PROCEPT BioRobotics Corporation (PRCT)
| Market Cap | 1.17B -53.8% |
| Revenue (ttm) | 337.34M +22.7% |
| Net Income | -109.76M |
| EPS | -1.95 |
| Shares Out | 57.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,761,973 |
| Open | 20.04 |
| Previous Close | 20.03 |
| Day's Range | 19.77 - 21.26 |
| 52-Week Range | 16.67 - 42.71 |
| Beta | 0.89 |
| Analysts | Hold |
| Price Target | 21.64 (+6.03%) |
| Earnings Date | Aug 4, 2026 |
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hype... [Read more]
Financial Performance
In 2025, PROCEPT BioRobotics's revenue was $308.05 million, an increase of 37.22% compared to the previous year's $224.50 million. Losses were -$95.57 million, 4.55% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for PRCT stock is "Hold." The 12-month stock price target is $21.64, which is an increase of 6.03% from the latest price.
News
Procept BioRobotics management to meet with Piper Sandler
Meeting to be held on August 10-13 hosted by Piper Sandler.
Kaplan Fox Urges PROCEPT BioRobotics Corporation (PRCT) Investors Seeking Recovery to Contact the Firm Before September 28, 2026
New York, New York--(Newsfile Corp. - August 5, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Comp...
Procept BioRobotics price target lowered to $23 from $30 at Evercore ISI
Evercore ISI lowered the firm’s price target on Procept BioRobotics (PRCT) to $23 from $30 and keeps an Outperform rating on the shares.
Procept BioRobotics price target lowered to $21 from $25 at Truist
Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $21 from $25 and keeps a Hold rating on the shares.
Procept BioRobotics price target lowered to $28 from $34 at TD Cowen
TD Cowen analyst Joshua Jennings lowered the firm’s price target on Procept BioRobotics (PRCT) to $28 from $34 and keeps a Buy rating on the shares. The firm said they…
Procept BioRobotics price target lowered to $20 from $24 at Baird
Baird lowered the firm’s price target on Procept BioRobotics (PRCT) to $20 from $24 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results…
Procept BioRobotics price target lowered to $25 from $35 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Procept BioRobotics (PRCT) to $25 from $35 and keeps an Overweight rating on the shares. The firm notes the…
Procept BioRobotics downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Nathan Treybeck downgraded Procept BioRobotics (PRCT) to Equal Weight from Overweight with a price target of $19, down from $34. Q2 introduced uncertainty about the aquablation pro...
Procept downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Procept BioRobotics (PRCT) to Market Perform from Outperform without a price target The company’s Q2 procedures came in 6% below Blair’s recently lowered estimate, the analyst...
Procept BioRobotics backs FY26 revenue view $390M-$410M, consensus $397.43M
Sees FY26 adjusted EBITDA loss $30M-$35M. Wood continued, “We also reached several important strategic milestones during the quarter, including completing enrollment in our WATER IV prostate cancer st...
PROCEPT BioRobotics Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 19% year-over-year to $94.5 million, driven by strong HYDROS system adoption and higher ASPs, though legacy AquaBeam accounts underperformed. Full-year guidance remains at $390–$410 million revenue and 54,000–56,000 U.S. procedures, with positive adjusted EBITDA expected in Q4. Direct-to-patient pilots and clinical milestones support long-term growth.
PROCEPT BioRobotics Earnings release: Q2 2026
PROCEPT BioRobotics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
PROCEPT BioRobotics Quarterly report: Q2 2026
PROCEPT BioRobotics has published its Q2 2026 quarterly earnings report on August 4, 2026.
PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...
Kaplan Fox Encourages PROCEPT BioRobotics Corporation (PRCT) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - August 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Comp...
Kaplan Fox Reminds PROCEPT BioRobotics Corporation (PRCT) Investors Seeking Recovery of the Lead Plaintiff Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Comp...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2026 in PROCEPT BIOROBOTICS CORPORATION Lawsuit - PRCT
Institutional investors and fiduciaries may need to assess PRCT losses tied to allegations that Procept's undisclosed handpiece discount program inflated recurring revenue metrics and pulled forward d...
Procept BioRobotics assumed with Neutral from Buy at UBS
UBS analyst Patrick Wood downgraded Procept BioRobotics (PRCT) to Neutral from Buy with a price target of $20, down from $30, after assuming coverage of the name. Demand growth has…
Procept BioRobotics assumed with Neutral from Buy at UBS
UBS downgraded Procept BioRobotics (PRCT) to Neutral from Buy with a $20 price target after assuming coverage of the name.
PROCEPT BIOROBOTICS CORPORATION (PRCT) INVESTOR ALERT Investors With Large Losses in PROCEPT BioRobotics Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026
SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transfor...
Procept BioRobotics downgraded to Hold from Buy at Truist
Truist downgraded Procept BioRobotics (PRCT) to Hold from Buy with a price target of $25, down from $30, citing lowered confidence in the company’s procedure growth re-acceleration prospects. Procedur...
PROCEPT BioRobotics Slides: Conference presentation
PROCEPT BioRobotics has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Procept BioRobotics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar initiated coverage of Procept BioRobotics (PRCT) with an Outperform rating and $30 price target Over next 12 mon, a positive WATER IV trial will expand…
Leerink downgrades Procept BioRobotics to Market Perform, lowers target to $29
As previously reported, Leerink analyst Mike Kratky downgraded Procept BioRobotics (PRCT) to Market Perform from Outperform with a price target of $29, down from $31. With the stock approaching the…